Edition:
India

AngioDynamics Inc (ANGO.OQ)

ANGO.OQ on NASDAQ Stock Exchange Global Select Market

19.76USD
24 Apr 2018
Change (% chg)

$-0.14 (-0.70%)
Prev Close
$19.90
Open
$19.91
Day's High
$20.03
Day's Low
$19.65
Volume
36,011
Avg. Vol
86,023
52-wk High
$20.70
52-wk Low
$14.81

Latest Key Developments (Source: Significant Developments)

AngioDynamics Q3 Earnings Per Share $0.37
Thursday, 29 Mar 2018 

March 29 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS REPORTS FISCAL 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.25.Q3 GAAP EARNINGS PER SHARE $0.37.Q3 SALES $83.9 MILLION VERSUS I/B/E/S VIEW $84.8 MILLION.Q3 EARNINGS PER SHARE VIEW $0.19 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 SALES $345 MILLION TO $350 MILLION.SEES 2018 ADJUSTED EARNINGS PER SHARE $0.70 TO $0.74.ANGIODYNAMICS - ‍ EXPECTS ITS ADJUSTED EARNINGS PER SHARE IN RANGE OF $0.64 TO $0.68, EXCLUDING ANY IMPACT FROM 2017 TAX REFORM ACT​ FOR FY 2018.FY2018 EARNINGS PER SHARE VIEW $0.71, REVENUE VIEW $346.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Angiodynamics Receives FDA Expedited Access Pathway Designation For Nanoknife System For Treatment Of Stage III Pancreatic Cancer
Thursday, 25 Jan 2018 

Jan 24 (Reuters) - Angiodynamics Inc ::ANGIODYNAMICS RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE NANOKNIFE® SYSTEM FOR THE TREATMENT OF STAGE III PANCREATIC CANCER.ANGIODYNAMICS INC - ‍FDA GRANTED EXPEDITED ACCESS PATHWAY DESIGNATION TO COMPANY'S NANOKNIFE SYSTEM​.  Full Article

AngioDynamics Says U.S. Tax Reform To Have Impact Of $0.02- $0.04 On Non-GAAP Adjusted EPS In FY 2018
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS SAYS U.S. TAX REFORM ACT TO HAVE AN IMPACT IN RANGE OF $0.02- $0.04 ON NON-GAAP ADJUSTED EPS IN FY 2018 -SEC FILING.  Full Article

AngioDynamics Q2 GAAP Earnings Per Share $0.01
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - AngioDynamics Inc ::ANGIODYNAMICS REPORTS FISCAL 2018 SECOND QUARTER FINANCIAL RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.16.Q2 GAAP EARNINGS PER SHARE $0.01.SEES FY 2018 SALES $345 MILLION TO $350 MILLION.Q2 SALES $86.7 MILLION VERSUS I/B/E/S VIEW $88.4 MILLION.Q2 EARNINGS PER SHARE VIEW $0.16 -- THOMSON REUTERS I/B/E/S.REAFFIRMS FY 2018 ADJUSTED EARNINGS PER SHARE VIEW $0.64 TO $0.68 EXCLUDING ITEMS.FOR 2018, COMPANY IS REDUCING ITS PREVIOUSLY ANNOUNCED NET SALES AND FREE CASH FLOW GUIDANCE.CO NOW EXPECTS ITS FISCAL YEAR 2018 NET SALES IN RANGE OF $345 TO $350 MILLION.  Full Article

AngioDynamics reports fiscal 2017 first quarter results
Wednesday, 5 Oct 2016 

AngioDynamics Inc : AngioDynamics reports fiscal 2017 first quarter results . Q1 adjusted non-GAAP earnings per share $0.17 . Q1 sales $88.1 million versus I/B/E/S view $86 million . Q1 earnings per share $0.04 . Q1 earnings per share view $0.13 -- Thomson Reuters I/B/E/S . Sees FY 2017 adjusted earnings per share $0.62 to $0.65 . FY2017 guidance remains unchanged . FY2017 earnings per share view $0.63, revenue view $358.6 million -- Thomson Reuters I/B/E/S .Sees FY 2017 sales $355 million to $360 million.  Full Article

AngioDynamics names Michael Greiner as new CFO
Monday, 25 Jul 2016 

AngioDynamics Inc : AngioDynamics appoints Michael C. Greiner as new chief financial officer .Greiner most recently served as chief financial officer at extreme reach.  Full Article

Intouch Health appoints Joseph Devivo as new CEO
Tuesday, 19 Jul 2016 

Intouch Health: Says Intouch Health announces new CEO . Intouch Health says appointed Joseph M. Devivo as its new chief executive officer .Says Devivo was most recently President, CEO and Director Of AngioDynamics.  Full Article

Angiodynamics reports Q4 loss $1.21/shr
Wednesday, 13 Jul 2016 

Angiodynamics Inc : Angiodynamics reports fiscal 2016 fourth quarter and full year results . Sees Q1 adjusted shr $0.11 to $0.14 . Q4 shr loss $1.21 . Sees Q1 sales $84 mln to $87 mln . Q4 sales $93.4 mln vs I/B/E/S view $88.4 mln . Q4 shr view $0.16 -- thomson reuters I/B/E/S . Sees FY 2017 adjusted shr $0.62 to $0.65 . Q4 adjusted non-GAAP shr $0.19 excluding items . Sees FY 2017 sales $355 mln to $360 mln . Sees FY2017 free cash flow guidance of greater than $30 mln . FY2017 shr view $0.66, rev view $358.6 mln -- Thomson Reuters I/B/E/S .Q1 shr view $0.14, rev view $86.4 mln -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-AngioDynamics Q3 Earnings Per Share $0.37

* ANGIODYNAMICS REPORTS FISCAL 2018 THIRD QUARTER FINANCIAL RESULTS